TAKEDA PHARMACEUTICAL CO LTD Chief Transformation Officer Duprey Lauren Rusckowski sold 34,535 shares at $18.54 per share on Sep. 14, leaving her with 191,522 shares. The transaction represented about 15.3% of her prior holding, giving investors a precise view of the sale’s size and remaining ownership.
Key Highlights
- Duprey Lauren Rusckowski serves as TAKEDA PHARMACEUTICAL CO LTD’s Chief Transformation Officer.
- The transaction took place on Sep. 14, 2026.
- The sale was classified under transaction code S.
TAKEDA PHARMACEUTICAL CO LTD (NYSE: TAK) Chief Transformation Officer Duprey Lauren Rusckowski sold 34,535 shares at $18.54 per share. The transaction left Rusckowski with 191,522 shares.
Sale Details and Transaction Classification
The transaction occurred on Sep. 14, 2026, and involved shares of TAKEDA PHARMACEUTICAL CO LTD. Transaction code S identifies the trade as a sale. Rusckowski’s position as Chief Transformation Officer was listed alongside the transaction. The reported sale price was $18.54 for each share transferred.
Remaining Ownership After the Transaction
Rusckowski’s post-transaction holding stood at 191,522 shares. The 34,535-share sale represented about 15.3% of her prior shares holding. The percentage is tied to her ownership before the transaction, while the 191,522 figure reflects the shares remaining afterward.
FAQs
Q: How many TAKEDA PHARMACEUTICAL CO LTD shares did Duprey Lauren Rusckowski sell?
A: The filing reports that Duprey Lauren Rusckowski sold 34,535 shares of TAKEDA PHARMACEUTICAL CO LTD. It lists the transaction price as $18.54 per share.
Q: How many shares did Takeda’s Chief Transformation Officer retain?
A: Duprey Lauren Rusckowski owned 191,522 shares after the transaction. She is identified as TAKEDA PHARMACEUTICAL CO LTD’s Chief Transformation Officer.
Q: When did the Takeda insider share sale occur?
A: The sale occurred on Sep. 14, 2026, according to the filing. It was recorded under transaction code S, which identifies the transaction as a sale.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.